Table 3. Pregnancy Risk Classification of Some of the Most Used Targeted Therapies and Immunotherapies in Medical Oncology.

Drug	Pregnancy/neonatal complication	Teratogenic
Imatinib	Not associated	Yes
Rituximab	Neonatal B-cell depletion	Not associated
Trastuzumab	Oligohidramnios	Not associated
Lapatinib	Possibly oligohydramnios	Yes (animal studies)
Bevacizumab	Possibly pre-eclampsia	No data
Ipilimumab	Abortion, stillbirths, premature delivery and higher incidence of infant mortality	Not associated
PD-1/PD-L1 inhibitors	Abortion, stillbirths, premature delivery and higher incidence of infant mortality	Not associated